← All Studio courses Studio · HSCI 485

Psychedelic-Assisted Medicine: Science and Practice

Decks for studio time, one for each lesson

Each deck guides studio time for its lesson: questions answered on students' devices, work in pairs and small groups, peer activities, and discussion as a class. A deck can also be presented without a room, worked through on your own (the recorded walkthroughs are being prepared, and until a deck's walkthrough is recorded its self-study format runs without the voice), or printed as a facilitator guide. All 12 decks are ready.

Lessons

12 of 12 decks ready
L · 01
Psychedelics and Psychedelic-Assisted Therapy: Definitions, Effects and How to Weigh ClaimsOne British Columbia coastal town's evidence notes after an unlicensed psilocybin store opens, from the narrow and broad meanings of "psychedelic", the four groups by primary mechanism, how Canadian schedules and national surveys sort the same drugs, psychedelic-assisted therapy compared with a daily medication and with supervised esketamine, and the lawful routes in Canada as of October 2026, through the four domains of subjective change, the 5D-ASC, MEQ30, Ego Dissolution Inventory and Challenging Experience Questionnaire, the complete mystical experience criterion and what research scales, qualitative studies and user-reported sources can establish, to the Canadian Substance Use Survey and its questionnaire changes, Monitoring the Future, microdosing, retreats and storefronts, and the growth of research, the hype cycle, the six-item checklist and where a claim was reported.
L · 02
Histories: Ceremony, Canadian Psychiatry, Prohibition and RevivalOne town museum's exhibit with a room for each period, reviewed panel by panel: four ceremonial traditions, their suppression by church and state and Canada's potlatch ban, Huautla after Wasson's article, the four harms and eight principles of an Indigenous-led consensus and four questions for any account of ceremony, Osmond and Hoffer and the word "psychedelic", Hollywood Hospital in the archive and in a magazine, the psycholytic and psychedelic models, risks and odds ratios from randomized trials and why summed counts differ from a pooled estimate, MKUltra, Cameron's depatterning, the Nuremberg Code and Canada's responses, the three layers of control that ended the first research era, the Good Friday Experiment compared with Griffiths et al. (2006), the Ricaurte retraction, the reopening of legal access in Canada from 2017 to 2022, and five lessons for practice.
L · 03
Pharmacology of Psychedelics: Receptors, Pharmacokinetics, Dose and InteractionsOne New Brunswick hospital clinic's pharmacology briefing for a psilocybin trial, from affinity, efficacy, antagonism and occupancy, the ketanserin blockade studies, the saturating occupancy curve and the molecular routes of LSD, MDMA, ketamine and ibogaine with the evidence behind each, through psilocybin as a prodrug, oral DMT and the beta-carbolines, measured onsets, peaks and offsets and the length of a session, infusions and fixed dosing, to tolerance, cross-tolerance and the self-administration evidence, and the three mechanisms a medication review screens for, antidepressants and tapering, serotonin toxicity, the lithium signal, ibogaine and the heart, and client-facing interaction charts.
L · 04
How Psychedelics Change the Brain: Networks, Plasticity and LearningOne New Brunswick hospital's four-panel explainer on how psychedelics might work, from what fMRI, arterial spin labelling, PET and MEG measure, the default mode network under psilocybin and LSD, observation, measure and theory, thalamic gating and Fisher's z for a small imaging study, through spines, BDNF and psychoplastogens, the evidence by organism, three proposed triggers, critical periods, ketamine and the human PET result, to fear extinction and its circuit, reconsolidation, MDMA in mice, rats and volunteers, the extinction retention index and the psilocybin amygdala findings, and the chain from receptor to recovery, four models of lasting change, non-hallucinogenic analogues and five gaps between animal findings and patients.
L · 05
The Psychedelic Experience: Mystical States, Set and Setting, Expectancy and BlindingOne northwestern Ontario city's protocol for a randomized trial of psilocybin-assisted therapy for depression, from the pharmacological and experiential accounts, the MEQ30, EBI, insight questionnaires and AAQ-II, the complete mystical experience criterion and correlation, prediction and mediation, through set and the three layers of setting, the history from Hollywood Hospital to the Johns Hopkins guidelines and FDA guidance, the evidence on set, music, alliance and environment and the ReSPCT reporting guidelines, functional unblinding, the share of correct guesses and the Bang blinding index for each arm, active placebos, instructions and blinded raters, and the debate over whether the experience is necessary, to the Challenging Experience Questionnaire, frequency estimates in three kinds of sample, meaning-making and extended difficulties.
L · 06
Safety, Screening and Risk ManagementOne Nova Scotia town's hospital safety manual for its esketamine clinic and an authorized psilocybin trial, from blood pressure timed to each drug, MDMA hyperthermia and hyponatremia, the corrected QT interval and ibogaine, the 5-HT2B question for repeated dosing and ketamine cystitis, through psychosis and mania in trials and in Ontario health records, suicidality in the COMP360 trials, the risk difference, relative risk and number needed to harm with their confidence intervals, and the rule of three, and through exclusion criteria, thresholds as conventions, deferral and stabilization, medication review and unfair exclusion, to the response ladder from reassurance to emergency transfer, rescue medication, discharge and aftercare, and the peer support lines, sanctuary spaces and legal limits outside clinics.
L · 07
The Therapeutic Process: Preparation, Dosing Sessions and IntegrationOne Alberta hospital's trial team writing a participant handbook, "What happens, and when", from the four phases of psychedelic-assisted therapy, the psycholytic and psychedelic traditions, the MAPS, Hopkins and Accept, Connect, Embody models, ketamine-assisted psychotherapy and Roots to Thrive, what placebo-controlled trials cannot show about the therapy and clinician hours per participant, through the alliance, intentions, psychoeducation that promises nothing, consent obtained while sober and the safety plan, and the session day as a supervised clinical process with its team, non-directive support, monitoring and record, to integration and its six facets, outcome measures and referral signals, and, as legal information, the two provisions that limit preparation and integration support and the four authorized routes.
L · 08
Psilocybin, Ketamine and Depression, Anxiety and End-of-Life DistressOne Nova Scotia town's evidence brief on psilocybin, LSD, ketamine and esketamine, from the forms of distress in serious illness, the two 2016 psilocybin trials in people with cancer, their crossover design, follow-up and safety, and palliative access in Canada through section 56 exemptions and the Special Access Program, through the early psilocybin trials for depression, the trial compared with escitalopram, the COMP360 program from phase 2b to its company-reported phase 3 results, LSD (DT120), four checks on a company topline and two meta-analyses that rate certainty differently, and the esketamine trials, approvals and controls, ELEKT-D compared with electroconvulsive therapy, ketamine-assisted psychotherapy and private clinics, to response, remission, the number needed to treat with its interval, durability, comparators and the gap between trial and clinic populations.
L · 09
MDMA-Assisted Therapy for PTSD: Evidence, Regulation and Research IntegrityOne Manitoba city's board briefing on MDMA-assisted therapy for PTSD: the conflicting animal, imaging and clinical evidence behind the proposal, one course of treatment with its co-therapist team, inner-directed stance and rules on touch, and the CAPS-5 with response, loss of diagnosis and remission; MAPP1 and MAPP2, the placebo-with-therapy response, the number needed to treat and its denominator, safety, durability and the missing head-to-head comparison; the regulatory path, functional unblinding, the criticisms and responses, the complete response letter, the retractions, the status in October 2026 and Australia's rescheduling; and the Vancouver site, the layers of protection and the safeguards for touch, recording, teams, monitoring and reporting.
L · 10
Psychedelics and Addiction: Alcohol, Tobacco, Opioids and Community ModelsOne Saskatchewan city's addictions council review of psychedelic approaches to addiction: the 1960s LSD meta-analysis and its fading effect, four conflicting psilocybin studies in alcohol use disorder, heavy drinking days, the smoking pilot trial with its odds ratio, risk difference and number needed to treat, the ketamine trials and the evidence behind each proposed mechanism; ibogaine's observational evidence, the QT interval, the case series of deaths, the rule of three, lost tolerance under the Canadian guideline, magnesium and public funding; ayahuasca's two plants, settings, Canadian law and religious exemptions, the research on ayahuasca and substance use, the 2013 study in a First Nations community, Indigenous-led ethical principles and the evaluations of Roots to Thrive; and the evidence ladder, the recurring threats to validity, the benchmarks from standard treatment, the conversion of an odds ratio to a number needed to treat and where psychedelic-assisted therapy could sit beside standard care.
L · 11
Access, Regulation and Practice in Canada and the WorldOne southern British Columbia town's brief of legal information on psychedelic access, from the phases of clinical research, review by the FDA, the EMA and Health Canada with their expedited programs, scheduling, the esketamine risk management program and the likelihood of approval, through the three layers of Canadian law, section 56 exemptions, the Special Access Program, clinical trials, the Controlled Substances Regulations of 1 October 2026, the Toth and Lance decisions and Alberta's licensing of treatment services, to the access models of Australia, New Zealand, Germany, the Czech Republic, the Netherlands, Oregon, Colorado and New Mexico with the United States federal developments of 2026, four criteria for rating models and both sides of the debate over a regulated public health model, and unlicensed storefronts, retreats, decriminalization, user-led resources, harm reduction principles and the limits of lawful practice.
L · 12
Ethics, Equity, Training and the Future of Psychedelic PracticeOne British Columbia city's plan for an outpatient psychedelic-assisted therapy service: the four features of the altered state, the seven components of consent obtained while sober, the rules on touch, relationships and supervision in four dated sources, the 2019 disclosure from a Canadian trial site and why each safeguard failed; who may prescribe and deliver care in British Columbia, three models of care, dated training programs, Phelps's competencies and the experiential training debate with the Canadian legal position; the eight ethical principles of traditional Indigenous medicine, Two-Eyed Seeing, Canadian and provincial commitments, the Nagoya Protocol, trial diversity and the clinician hours and cost of a course of therapy; and patents, investors, the Field Trip clinic chain, the rules on marketing claims, non-hallucinogenic analogues, a research agenda and the six decisions in designing a service.
Students: join studio time. Open the join page and enter the four-letter code on the main screen, or scan the QR code. Join studio time